The availability of appropriate antimicrobial medicines is important to fight antimicrobial resistance. The FAMHP strives to keep or to bring essential antimicrobial products on the market and to keep healthcare professionals and patients well informed. Again, as a result of those efforts: amoxicillin for injection/infusion has been back on the market in Belgium since April.
The FAMHP systematically monitors the availability of antibiotics and alternatives. For new antibiotics, the FAMHP proactively contacts marketing authorisation holders to suggest their marketing in Belgium. For antibiotics no longer for sale, we look for solutions by consulting the relevant marketing authorisation holders or other companies. Earlier this year, four other essential antimicrobial medicines already became available (again) in Belgium: amukin, zerbaxa, broxil and rukobia.
After consulting with the FAMHP, Delbert Laboratories has taken over the marketing authorisation for Clamoxyl 1g I.V.-I.M. (amoxicillin) that was suspended by GSK in December 2021. Delamoxyle 1 g, powder for solution for injection/infusion (amoxicillin) (Delbert Laboratories) is the same product as Clamoxyl 1g I.V.-I.M. (amoxicillin) (GSK), which is administered intravenously or intramuscularly.
Delamoxyle 1 g, powder for solution for injection/infusion (amoxicillin) by Delbert Laboratories, belongs to the group of penicillins. It is used to treat bacteria-induced infections in various parts of the body. Delamoxyle is usually administered for the urgent treatment of a serious infection or when patients cannot take this medicine orally.
To reduce the risk of shortages of this essential antimicrobial medicine, its production is based in Europe.